Available Technologies

Freshly Frozen Tissue/Cell Microarrays that Retain Native Protein Integrity

1995 — Freshly frozen tissue / cell microarrays are useful for many biological applications, but generating them is time-consuming, inconvenient, and failure-prone. Generating a freshly frozen tissue or cell microarray involves freezing a block of embedding material, making holes in the block, and inserting a frozen tissue sample or optionally frozen or thawed cell sample into the holes. The procedure needs to be completed at temperatures below 0°C, so making holes in the receiving block or inserti...

Prostate Cancer Diagnostic, Prognostic and Therapeutic Tool using RAD9 Gene

2081 — Prostate cancer is the second most prevalent cancer type in American men and is now the second leading cause of cancer death within this group. Currently, there are a number of treatment options available, including surgery, radiation, chemotherapy, hormone therapy, and alternative approaches. Selecting one of these options often hinges on a number of factors including age, overall health, cancer grade, tumor localization/metastasis, and potential side effects. A cure for prostate cancer...

Discovery of a novel microRNA in normal and tumor-related Human B cells

2227 — There is evidence that structural or functional alterations of microRNAs are associated with tumorgenesis. This technology represents a way to identify B cell malignancies and provides a method to treat a given cancer by restoring the level of microRNA expression associated with that cancer to normal. The discovery of a microRNA that is differentially expressed during normal B cell differentiation and malignant transformation has potential to transform future B cell lymphoma diagnostics ...

Cancer treatment for Tumor Cells Using RSL3

m10-018 — Drug candidate for cancer treatment is selective for cancer cells Patent Pending (US 61/274,949 & WO/2008/103470) ~ see link below. Available for Licensing and Sponsored Research Support STV Reference: IR M10-018 & M06-044

Mouse for prostate cancer drug development

2668 — Prostate cancer is the second leading cause of cancer death in men. Although various therapeutic modalities exist currently (surgical, anti-hormone therapy, etc.) for prostate cancer, malignant and aggressive types of this disease remain refractory to current standard practices. Indeed, current research and development has focused on the formulation of new classes of drugs/compounds that may help improve survival. Animal models of prostate cancer are essential and needed for pre-clinical...

Cervical Cancer Gene Markers for Targeted Therapy

2847 — Current treatment modalities for invasive cervical cancer result in largely unpredictable patient response. As a result, there is a pressing need for rational design of predictive biomarkers that can better guide treatment strategies in order to provide safer and more efficacious therapy. Recent advances in genomic and proteomic technologies have shown great promise in identifying biomarkers to enable more advanced diagnosis and allow for personalized therapy to improve clinical outcomes...

Novel treatments for breast cancers containing mutations in p53 including Fatostatin that target SREBP and SCAP

cu12116 — Mutations to the tumor suppressor gene p53 are found in 25-30% of all human breast cancers. Certain p53 mutants upregulate target genes such as the genes of the Mevalonate pathway, a pathway that facilitates the synthesis of hormones, steroids, and other bioactive small molecules. This overexpression is facilitated by the transcription factors SREBP and SCAP. In human cancer cells bearing p53 mutations, inhibiting the action of SREBP and SCAP with small molecules such as Fatostatin leads...

PCR assay detects mutant genes with 50 to 100-fold increase in sensitivity

cu12130 — Polymerase chain reaction (PCR) involves separation of double stranded DNA and sequential amplification of target genes in order to detect gene sequences. This technology encompasses two modifications to increase the sensitivity of PCR, via preferential replication of the target of interest. One method involves a primer which allows for amplified alleles to denature at lower temperatures while creating a thermostable endonuclease site in wild-type alleles that lack a native restriction s...

Insulin-Like Growth Factor Protein 3 (IGF-BP3) for Inhibiting Tumor Growth

1266 — “Lead Inventors: lrena Kirman, MD, Ph.D. and Richard L. Whelan, MD Surgical Trauma Encourages Cancer Recurrence: This invention provides a method of preventing the proliferation of metastases and recurrence of cancer following open surgical resection of tumor mass. This is accomplished by monitoring and modulating the levels of the 43-45kD protein insulin-like growth factor binding protein-3 (IGFBP-3), the major insulin-like growth factor binding protein, in the patient's circulation. Fo...

Black Cohosh Extract and Triterpene Glycoside Act as Anti-Neoplastic Agent or in Combination with Existing Compounds Results in Synergistic Anti-Cancer Action

2425 — Related Technologies: IR# & IR# Anti-Cancer Drug Toxicity and Resistance in Patients This invention is an extract from, and a particular component of, black cohosh (a flowering plant native to much of the Eastern United States) that alone has shown anti-cancer effects that are non-toxic. In addition, when the isolated component, a triterpene glycoside, is combined with the known anti-cancer agent paclitaxel, a synergistic effect was observed in inhibiting growth of breast can...

Metabolite Biomarker to Regulate Cancer Cell Growth

m10-032 — Cancer cells differ from most adult cells in their high uptake of glucose. The glucose is subsequently converted into lactate even in the presence of oxygen, allowing cells to accumulate glycolytic intermediates for cell biosynthetic processes. A key enzyme in the glycolytic pathway, pyruvate kinase M, has been implicated in determining the metabolic phenotype of cancer cells as opposed to normal adult cells. Pyruvate kinase M mRNA is alternatively spliced to produce two isoforms of the ...

Inhibitors of Human 9-cis Retinol Dehydrogenase Linked to Cancer Detection

740 — “Name of the inventor: William Blaner Cancer Detection Possible with Human Retinol Dehydrogenase: Methods of detecting compounds that are capable of inhibiting the enzymatic activity of human 9-cis retinol dehydrogenase in in-vitro and in-vivo conditions are described. The compounds capable of inhibiting human 9-cis retinol dehydrogenase include naturally occurring and synthetic retinoids and lipids. A method for detecting a predisposition to cancer or a disease associated with either a...

Post-surgical cancer recurrence prevention by inhibition of metastatic cell tumor growth

1642 — This invention provides a method of preventing the proliferation of metastases and following surgery appears to be due to proteolytic cleavage mediated by matrix metalloproteinase 9 lrena Kirman, MD, Ph.D. and Richard L. Whelan, MD United States Issued Patent# 7166,288 and patent pending Licensing Status: Available for Licensing and Sponsored Research Support Publications: Surgery (2004) 136 (2): 205-9; Disease of the Colon and Rectum (2004) 47 (6): 91 1-1 8; Surg En...

Discovery of RAS-selective drugs to treat cancer

m06-044 — Many anti-cancer drugs currently in use are toxic compounds that cause significant side effects. These agents are often not particularly selective for tumor cells and can cause unwanted damage or death to normal cells. Furthermore, the high doses required to maintain the efficacy of many anti-cancer drugs results in increased toxicity in patients. Drug resistance is also an issue for cancer therapies: high doses and repeated treatments can produce tumors that are resistant to available c...

Cancer Detection with Mutant-Enriched DNA Sequencing for Small Tumor PIK3CA Mutations

2153 — Altered regulation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway has been associated with cancer development. Somatic mutation of one PI3K signaling component, PIK3CA (phosphatidylinositol 3-kinase, catalytic subunit p110a), has been identified in many tumor types including early lesions of breast cancer carcinoma, hepatocellular carcinoma, and gastric carcinoma, as well as head and neck squamous cell carcinoma (HNSCC). Given the involvement of PIK3CA in many aspects of t...

Early Detection of Liver Cancer by Methylated Tumor DNA in Blood

2218 — Hepatocellular carcinoma (HCC) is one of the most common and serious human cancers; nearly 500,000 patients are diagnosed annually. A lack of effective therapeutics and advanced stage diagnosis cause most patients to die with in a year of diagnosis. While HCC is highest in East Asia and Sub-Saharan Africa, it is also increasing in US. Current screening tests to detect early stage HCC use a combination of alpha-fetoprotein (AFP) analysis and ultrasound. However, though screening of early ...

Inhibiting Insulin-Like Growth Decreases Cancer Cell Growth, Improves Chemotherapy Results

2319 — Inhibition of Insulin-like Growth Factor I Receptor Kinase (IGF1 RK) decreases cancer cell growth and may also render cancer cells more susceptible to chemotherapy. The compound picropodophyllin shows exquisite selectivity for the IGF1 RK, and thus could lead to a new class of chemotherapeutic drugs. Currently there is no drug on the market that acts upon the IGF1 RK. Development of such a drug is, therefore, an emerging macromolecular target of great interest. Moreover, there is an emer...

Gab2 Gene Therapeutic Target for Melanoma

2344 — Melanoma is the fifth most common cancer in the US. If diagnosed in the early stages, melanoma can be treated with surgery; however metastatic disease has a poor prognosis with a median survival of 6-9 months. There is no therapy for thicker or metastatic melanomas proven to have a significant impact on survival. Therefore, there is an urgent need to identify novel therapeutic targets and develop new treatment strategies for this disease. This invention is the identification of a ...

Diffuse Optical Tomography Probe for Breast Cancer Imaging

cu12094 — Breast cancer affects approximately 1 in 8 women in the United States and the incidence of breast cancer throughout the world is increasing. With more than 200 000 new cases every year, it accounts for 28% of all new cancers diagnosed in women. Because of growing awareness, more women today are undergoing breast cancer screening, such as x-ray mammography. However, there have been noted cases of poorly maintained mammography machines emitting excessive x-ray radiation that can lead to ca...

Wireless Handheld Optical Probe for Breast Cancer Imaging

cu12093 — Breast cancer affects approximately 1 in 8 women in the United States and the incidence of breast cancer throughout the world is increasing. With more than 200 000 new cases every year, it accounts for 28% of all new cancers diagnosed in women. Because of growing awareness, more women today are undergoing breast cancer screening, such as x-ray mammography. However, there have been noted cases of poorly maintained mammography machines emitting excessive x-ray radiation that can lead to ca...

Using antibodies against human chorionic gonadotropin-related determinants to lyse measure and enrich malignant cells

309 — “Name of the inventor: Alexander Krichevsky Lysing Malignant Cells Using Antibodies against Human Chorionic Gonadotropin-Related Determinants A method of lysing malignant cells using antibodies against human chorionic gonadotropin-related determinants. Bringing Malignant Cells into Contact with Antibody for Human Chorionic Gonadotropin Malignant cells are brought...

Protease Polypeptide for Identifying Leukemia Treatment

674 — “Name of the inventor: Christian W. Schindler Leukemia Treatment Research Possible with Stat5-Specific Protease: A Stat5-specific protease polypeptide is described. The Stat5-specific protease is a partially-purified protease or a recombinant protease. A method for the identification of compounds or small molecules which regulate hematopoietic differentiation is proposed. A monoclonal or polyclonal antibody which specifically binds to the Stat5-specific protease is disclosed. Further, a m...

Isolated Fragments of Nucleoporin

909 — “Name of the inventor: Seth Lederman MD Protein Fragments for Immune Response Research: Isolated protein fragments of p62 nucleoporin including deletion isoforms and nucleic acid sequences encoding these deletion isoforms and pharmaceutical compositions methods for their use activating target genes are described. The method of inhibiting inflammation/ translocation of NF-6B /enhancing immune response comprises administering to a mammal an effective amount of an isolated polypeptide having...

Sodium Magnetic Resonance Imaging for Tumor Diagnosis, Treatment

810 — The ability to assess the chemotherapeutic efficacy against a tumor at an early stage has enormous utility. However, in vitro cytotoxicity assays are limited by the difficulty in obtaining fresh tumor tissue and culturing human cells in explant. In vivo assessment of chemotherapeutic efficacy is limited by the length of time required for a change in size in a measurable soft tissue lesion to occur, which can sometimes be weeks. In addition, some cancers metastasize predominantly in bone,...

Transformation Progression-Related Genes for Cancer Diagnosis and Therapy

proxyfisher5 — “Name of the inventor: Paul Fisher Cancer Diagnosis, Monitoring and Therapy with Polypeptide Composition Compositions and methods for cancer diagnosis, monitoring and therapy are disclosed. The pharmaceutical composition comprises a polypeptide and a physiologically acceptable carrier. Cancer Progression Monitored and Inhibited with Isolated Polypeptide The isolated polypeptide comprises a portion of a progression-related protein/a variant wherein the progression-related protein retains at...

Phosphorothioate Antisense Heparanase Oligonucleotides for Reduced Angiogenesis and Metastasis of Tumors

1103 — “Name of the inventor: Cy Stein Tumor Metastasis and Angiogenesis Reduction by Inhibition of Heparanase Protein Expression Antisense phosphorothioate oligonucleotides that specifically inhibit the translation of heparanase enzyme are described. Reduced Angiogenesis and Metastasis of Tumors with Pharmaceutical Composition Pharmaceutical compositions comprising antisense phosphorothioate oligonucleotides as active ingredients are used to reduce angiogenesis and metastasis of tumors in a subje...

Free Radicals in Cancer Treatment

1231 — “Name of the inventor: Paul Fisher Treating Cancer By Generating Melanoma Differentiation Associated Gene and Free Radicals in Cancer Cells: An effective amount of MDA-7 is generated by administering MDA-7 nucleic acid, MDA-7 protein or their functional equivalents, or by up-regulation of the endogenous MDA-7 gene or stabilization of the MDA-7 mRNA in the cancer cell. Free radicals are generated in the cancer cell by exposing the cancer cell to an effective amount of ionizing radiation...

Colon cancer inflammatory bowel disease patients

1640 — “Lead Inventors: lrena Kirman, MD, Ph.D. and Richard L. Whelan, MD Colon cancer risk and diagnosis for patients with inflammatory bowel disease: The invention provides a body fluid-based approach to diagnose, in a population of patients with inflammatory bowel disease (IBD), an individual's risk of developing colon cancer. IBD is a chronic inflammatory condition of the digestive tract, and the classification of IBD includes patients with ulcerative colitis and Crohn's Disease. 1 milli...

Compounds for preventing restenosis after angioplasty or stent implantation

1911 — Related Technologies: IR# & IR# Prevention of vascular stenosis and restenosis in diabetic patients resistant to rapamycin : This technology provides new therapeutic strategies useful for the treatment and prevention of vascular stenosis and restenosis in diabetic and obese patients. Recent studies suggest that rapamycin resistance in diabetic and obese patients may be due to their elevated blood leptin levels. In addition, new research reveals that phosphatidylinositol 3-kin...

CONEXIC Algorithmic Software: Tracking the Genetic Footprints of Cancer

m11-079 — Systematic characterization of cancer genomes has revealed a staggering number of diverse aberrations that differ among individuals, such that the functional importance and physiological impact of most tumor genetic alterations remain poorly defined. Multiple new genes have been implicated in cancer through several existing techniques, but the most significant lesson from these studies is that each tumor is unique and typically harbors a large number of genetic lesions, of which only a f...

Diagnose and regulate glioblastoma tumor cells through transcription factor ATF5 activity

1649 — Transcription factor ATF5 is a protein involved in the growth and persistence of glioblastoma tumor cells. This technology provides both a method to diagnose and treat tumors through modulation of ATF5 activity. Given that ATF5 is implicated in several types of cancer, the efficacy of this technology also expands to tumors in the breasts, kidney, prostate, and colon and has shown tumor specific effectiveness, leaving healthy cells intact. By regulating ATF5 expression, it is possible to mini...

Mouse stem cells for cancer drug screening

585 — Rad9 was previously identified by Dr. Lieberman ( ) and promotes cell survival through the regulation of DNA repair and the activation of cell cycle checkpoints induced by DNA damage. Mouse embryonic stem (ES) cells with a targeted deletion of Mrad9, the mouse ortholog of the gene, were created to evaluate the function of the protein in mammals. Mrad9-/- ES cells and Mrad9+/- mice are both available for use in cancer research. Both the mouse and cell lines, with deficient response...

Glycoconjugates Synthesis of the Lewis Y Epitope for Vaccine Therapies in Cancer Treatment

sk625 — “Name of the inventor: Samuel Danishefsky Cancer Treatment with Compound, Le.sup.y Tetrasaccharide Determinant A method for the synthesis of an allyl pentasaccharide, related oligosaccharide ceramides and other glycoconjugates useful as vaccines in an adjuvant therapy. A method of inducing antibodies in a subject, wherein the antibodies are capable of specifically binding with epithelial/colon tumor cells comprises administering to the subject an amount of a compound which contains a Le.sup...

Nucleic acid molecule biomarkers for cancer studies

601 — “Name of the inventor: Beth C. Levine Production, recovery, and purification of wild-type human beclin using a host-vector system: An isolated nucleic acid which encodes a wild-type human beclin and a mutant human beclin is described. A method of producing a wild-type human beclin using a host-vector system and method of recovery and purification of the wild-type human beclin are disclosed. Nucleic acid encoding a wild-type human beclin for cancer research: The isolated nucleic acid e...

Tumor Suppressor Gene

744 — A pharmaceutical composition which comprises an effective amount of the isolated tumor suppressor gene and pharmaceutically acceptable carrier capable of reversing the cancer phenotype of a cancer cell is also proposed. A knock-out animal resulting from the initial incorporation of the gene or its portion into its germ line is also described. Gene for Tumor Suppression: Alpha-1,6-dextran is a polysaccharide demonstrated to be a stable and non-toxic molecule through its use clinical...

Small Protein That Interacts With Ribonucleotide

824 — “Name of the inventor: Rodney J. Rothstein Protein Reacts with Ribonucleotide to Reduce Cell Division: An isolated Sml1protein or a homologue is described. A screening assay for identifying compounds that are capable of reducing the division rate of a cell by altering an interaction between a ribonucleotide reductase and a Sml1 protein in the cell is proposed. Cancer, Microbial Infection Treatment: A method of treating cancer/microbial infection through the administration of effective a...

Screening for Apoptosis Modulators

921 — “Name of the inventor: Taka-aki Sato Polypeptide for Studying Cell Apoptosis: An antisense oligonucleotide has a nucleic acid sequence capable of specifically hybridizing to an mRNA molecule encoding the polypeptide capable of binding a p75.sup.NTR receptor. An isolated nucleic molecule encodes a polypeptide capable of binding a p75.sup.NTR receptor and a purified version of polypeptide capable of binding a p75.sup.NTR receptor. A pharmaceutical composition comprises of a purified pol...

Detectably Labeled Porphyrin Compound for Identifying Sentinel Lymph Node

988 — “Name of the inventor: Mahmoud El-Tamer, M.D. Cancer Tumor Lesion Tissue Injected with Detectable Labeled Porphyrin Compound Method for the identification of sentinel lymph node particularly those with cancer using a detectably labeled porphyrin compound is described. Single Purified Porphyrin for Sentinel Lymph Node Identification A radio-labeled gamma emitting detectable labeled porphyrin compound is prepared and injected into a tissue surrounding a tumor lesion of a subject. Radioactive e...

Nucleic Acids Comprising Regions of the Rat PEG-3 Promoter for Cancer Cell Suppression and Death

1008 — “Name of the inventor: Paul Fisher Cancer Treatment Tested with a Nucleic Acid Comprising a Rat PEG-3 Promoter A method for treating cancer in a subject by administering a nucleic acid comprising a rat PEG-3 promoter operatively linked to a gene-of-interest like a tumor suppressor gene or a cytotoxic gene is described. PEG-3 Treatment Resulted in Growth Suppression or Death of Cancerous Cells The gene of interest is selectively expressed in cancerous cells in the subject and such expression...

Differentiation-Associated Sequences for Cancer Treatment and Vaccines

proxyfisher1 — “Name of the inventor: Fei Huang Cancer Diagnosis and Therapy with Isolated Polypeptide Compositions and methods for inhibiting cell growth, inducing terminal differentiation and cancer therapy are described. Polynucleotide Sequence Therapy for Inhibiting Cancer Development and Progression The isolated polypeptide comprises a portion of a differentiation-associated protein/a variant where the differentiation-associated protein comprises a sequence encoded by a polynucleotide sequence/a compl...

Detecting and Treating Prostate Cancer

proxyfisher4 — “Name of the inventor: Paul Fisher Prostate Cancer Detection by Determining Presence of Isolated Polypeptide Compositions and methods for the detection and therapy of prostate cancer are described. Diagnostic Kit for Detecting and Monitoring Progress of Prostate Cancer The isolated polypeptide comprises an immunologically active portion of a tumor-associated protein or a variant. A vaccine comprises an antigen presenting cell that expresses a polypeptide and a non-specific immune response e...

Progression Suppressed Gene 13 (PSGEN 13) as Gene Thrapeutic Cancer Treatment

1141 — “Name of the inventor: Paul Fisher Cancer Treatment with Progression Suppressed Gene 13 (PSGEN 13) Cloning and characterization of the complete rat and human PSGen 13 cDNAs, the associated nucleic acids and encoded amino acid sequences and the suppressive effects of increased levels of PSGen 13 on the malignant phenotype are described. Cancer Cell Growth Inhibited with Nucleic Acid Encoding a PSGen 13 Protein A method for inhibiting growth of a cancer cell with a nucleic acid encoding a PSGe...

Anti-Cancer Treatment with C-Terminal p53 Palindromic Peptide that Induces Apoptosis of Cells with Aberrant p53

1330 — More than 50% of human malignancies, including breast cancers, are associated with missense mutations or deletions of p53, a sequence-specific transcriptional factor involved in cell growth regulation. Therefore, a therapy directed at specifically killing p53-mutant cells would have wide application in targeted cancer therapies. The invention identified two polypeptides comprising a given segment of continuous amino acids (SEQ ID NO: 1, SEQ ID NO: 2) or at least two of each covale...

Genetic terminal disease treatment without negative immune response

1523 — In medicine, particularly for treatments of terminal diseases, there is a need for the ability to modify the genetics of cells. It is a well-known problem that by trying to insert foreign genes into a person’s cells, an immune response is thereby triggered, which can nullify the effects of the foreign genes. This problem has been a hindrance to the development of life-saving genetic treatments for cancer, heart disease and many other degenerative diseases. Therefore, there is an unmet ne...

Methods for Diagnosing and Treating Pediatric Neoplasm Cancer

1917 — The mortality from pediatric cancers can be reduced if tumors are diagnosed and treated at an early stage. Moreover, current treatment protocols can be invasive (surgery) or can produce deleterious side-effects. Side-effects are a particular concern in pediatric neoplasms because chemotherapy and radiation can interfere with growth and thus generate serious consequences. It is clear that alternative strategies for diagnosis and treatment of pediatric neoplasms are needed in order to achi...

Alzheimer's treatment using new class of small molecule HAT activators

2632 — Epigenetic modifications, particularly those affecting histone acetylation, have been implicated in a number of diseases. Addition of acetyl groups to histones by histone acetyltransferase (HAT) enhances gene expression while their removal by histone deacetylases (HDAC) reduces expression. Reduction in histone acetylation has been found in mood disorders and neurodegenerative diseases. Increasing histone aceylation by Histone Acetyltranferases (HAT) presents a promising therapeutic strat...

Cancer Treatment with Statin-Like Drug for Mutant p53 Tumors

m11-022 — Over 50 percent of human tumors contain mutations in the gene encoding p53, a protein thought to play a role in early carcinogenesis. Classically, this gene is thought to be a tumor suppressor that causes cancer through a loss of function. However, mutant p53 has recently been shown to exhibit gain-of-function properties as well, causing cancer formation by enabling normally suppressed pathways. One such oncogenic pathway activated by this mutation is the sterol biosynthesis pathway. Inhibit...

The use of TRPV3-directed compounds for prevention and treatment of non-melanoma skin cancers

cu13094 — Transient Receptor Potential Channel 3 (TRPV3) receptors are expressed in keratinocytes and influence cell proliferation and differentiation via a mechanism that regulate cytoplasmic calcium. This technology has identified TRPV3 as being dysregulated in human cutaneous Squamous Cell Carcinoma (cSCC). Furthermore, moderate TRPV3 activation with small molecule agonists has been found to arrest proliferation and reduce tumor size in human preclinical models. These findings suggest TRPV3 mod...

Cell culture technique to produce human and mouse prostate organoids

cu13124 — Prostate cancer is the leading cancer among men in the United States, with an annual incidence of over 144 per 100,000 men, and it is a heavily investigated disease. Most research currently being conducted on prostate cancer relies on the use of established, immortal cell lines to model the disease. However, these laboratory-based cell lines can differ from the actual prostate tissue in a human. Even with prostate tissue obtained via prostatectomy or cystoscopy, current methods fail to maint...

Anti-Cancer Agent Peptides Deliver Antisense Oligonucleotides to Regulate Cell Protein Expression

1102 — Cancer is the second leading cause of death in the United States. When cancer has metastasized, it can only be cured by systemic therapy, usually cytotoxic chemotherapy. However in this case chemotherapy is often ineffective. There are current attempts to develop new anti-cancer agents, including antisense oligonucleotides to specifically inhibit the translation of mRNA into protein. However, their use as therapeutic agents is limited because of intracellular transport and compartmentali...